We are monitoring the impact of COVID-19 on Migraine Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 3948
Share on
Share on

Global Migraine Drugs Market Size, Share, Trends & Growth Analysis Report – Segmented By Treatment (Preventive & Absorptive), Therapeutic Class (Triptants, Ergots & Others) & Region - Industry Forecast (2020 to 2025)

Pulished: February, 2020
ID: 3948
Pages: 186

Global Migraine Drugs Market Size (2020 to 2025)

The global migraine drugs market size was worth USD 4.23 billion in 2020. This market is growing at a CAGR of 4.87 % and will reach USD 5.32 billion by 2025.

Migraine is a typical kind of headache that occurs due to both nerves and blood vessels' involvement, mostly seen more in women than in men. There are two kinds of medications used to treat migraines, in which some are for the cure and others are for prevention.

Drugs that cure migraine:

  • Anticonvulsants (Topiramate)
  • Beta-Blockers (Propranolol)
  • Antihistamine (Cyproheptadine)
  • Botulinum Toxin
  • Histamine Calcium Channel Blockers (Verapamil)

According to the Migraine Research Foundation, migraine ranked as the 3rd most prevalent illness and 6th most disabling illness worldwide. Around 39 million in the United States and over 1 billion population is now suffering from migraine.

According to Medline article, nearly 12% of the U.S. population suffers from migraine headaches. The treatment of this migraine headache is treatable by using preventive medications. For Instance, a device known as the Cefaly Transcutaneous Electrical Nerve Stimulating device is approved by the FDA to treat migraines. This device increases the trigeminal nerve by emitting electric currents and provides temporary pain from a migraine.

MARKET DRIVERS:

Y-O-Y growth in the incidence of migraine among people, the rising population worldwide, and the growing demand for quality drugs are significant factors driving the growth of the global migraine drugs market. The incidence of migraine is higher in women than in men. The growing female population worldwide is a big plus to the global migraine drugs market expansion.

Additionally, factors such as increasing work pressure, high alcohol consumption, growing demand for quality drugs, changes in lifestyles, and awareness among patients associated with the prevention and treatment of migraine further increase the demand levels for the global migraine drugs market. Rising pharmaceutical R&D expenditures, increasing healthcare spending, and a high prevalence of migraines are expected to boost the growth rate of the global migraine drugs market during the forecast period.

Creating awareness over the availability of different treatment procedures for migraines in rural areas boosts the market demand. Investments in the development of new drugs by market players and other companies are also leveling up the growth rate of the market. Changes in lifestyles and rising stress levels among people are factors for the market to grow.

MARKET CHALLENGES: 

Side effects that connect with migraine drugs are hampering the growth of the market. Stringent rules and regulations by the government are also hindering the growth rate of the migraine drugs market. Also, the harmful effects of drugs and the increasing precedence of other therapies restrain the growth during the period.

Impact of COVID-19 on the global migraine drugs market:

Migraine is one of the medical conditions of headache. Many COVID-19 patients who had recovered have reported that they felt a headache-like migraine during the quarantine period. The sudden outbreak of COVID-19 has increased stress levels in a considerable amount of population across the world, thus reflected in the global increase of people suffering from migraines. The market for migraine drugs has seen a spike in demand since the beginning of the COVID-19 pandemic. Regions such as North America, Europe, and APAC had registered significant growth in 2020. Increased retail sales of triptans demanded by people with acute migraine conditions have accelerated the market to grow substantially. Analysts at Market Data Forecast have predicted that, with the support received from COVID-19, the global migraine drugs market will register new growth heights during the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Analysed

By Treatment, Therapeutic class, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global migraine drugs market has been segmented and sub-segmented based on treatment, therapeutic class, and region.

Migraine Drugs Market - By Treatment:

  • Preventive
  • Absorptive

Based on the treatment type, the preventive segment is likely to hold the most substantial market value share with the increasing knowledge over the therapies.

Migraine Drugs Market - By Therapeutic Class:

  • Triptants
  • Ergots
  • Others

Based on Therapeutics, the triptants segment holds the most considerable share market value of the Migraine Drugs Market. Escalating expenditure on healthcare is undoubtedly to push the demand for this category.

Migraine Drugs Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Geographically, the North American market is likely to dominate the global migraine drugs market growth due to the rise in several people suffering from headaches.

Asia-Pacific Market expects to have a high CAGR from 2020 to 2025 due to the successful initiatives taken by the governments of Asia Pacific countries to bring awareness towards migraine. In this region, India and China are the countries that contribute to the migraine drugs market.

In Europe and LAMEA regions, there is an increase in research and development activities, which is likely to surge up the market growth. Asia-Pacific to have substantial growth in the upcoming years.

KEY MARKET PARTICIPANTS:

Companies playing a promising role in the global migraine drugs market profiled in this report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories, Abbott, Aeriel BioPharma, Alder Biopharmaceuticals, Bayer, CoLucid, Eli Lilly, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, and Winston Pharmaceuticals.

HAPPENINGS IN THIS MARKET IN THE RECENT PAST:

  • In December 2019, Ubrelvy received FDA approval for Allergan, a new oral medication for migraine sufferers. This medicine is very effective in treating the migraine where the patient is unresponsive for other treatment procedures.
  • In January 2020, Eli Lilly launched a new medicine to treat migraines named Reyvow, and the FDA has given for approval. It is the first drug to treat pain and the sensitivity of light, sound, and nausea.
  • In September 2018, Teva’s Ajovy became the second CGRP medicine, which the US FDA has approved. Ajovy is the first and the only CGRP antibody that offers patients quarterly and monthly dosages.
  • In the same year, Eli Lilly and Company has received the US FDA acceptance for the approval of Emgality, a 120mg injection for the medicinal treatment of migraine only in adults.
  • Allergan’s Botox, a neurotoxin, is used as a preventive measure for the migraine market. It is the only drug that had the approval to apply for prevention. Botox is likely to face competition from the launch of Amgen/Novartis that target both chronic and separate parts that are having a migraine.
  • In May 2018, Aimovig was approved by the US FDA, which is a drug that helps treat chronic migraines. It is the first new class of migraine treatments called CGRP antagonists.
  • AOBiome therapy lpsis developed as a novel antibacterial agent AOB-203 for the prevention of migraine. The product is an ammonia-oxidizing bacteria AOB, which produces nitric oxide that regulates the swollen parts and dilates blood vessels that decrease blood pressure-related to migraines.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Treatment                  

                                5.1.1 Introduction           

                                5.1.2 Preventive              

                                5.1.3 Abortive   

                                5.1.4  Y-o-Y Growth Analysis, By Treatment         

                                5.1.5  Market Attractiveness Analysis, By Treatment       

                                5.1.6  Market Share Analysis, By Treatment        

                5.2 Therapeutic                

                                5.2.1 Introduction           

                                5.2.2 Triptents  

                                5.2.3 Ergots        

                                5.2.4 Others      

                                5.2.5 Y-o-Y Growth Analysis, By Therapeutic       

                                5.2.6 Market Attractiveness Analysis, By Therapeutic     

                                5.2.7 Market Share Analysis, By Therapeutic       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Treatment

                                                6.1.3.3 By Therapeutic

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Treatment

                                                6.1.4.3 By Therapeutic

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Treatment

                                                6.1.5.3 By Therapeutic

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Allergan                       

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Endo International                  

                8.3  GlaxoSmithKline                      

                8.4 Impax                           

                8.5 Pfizer                            

                8.6 Aegis Therapeutics                  

                8.7 Alder Biopharmaceuticals                     

                8.8 Astellas                        

                8.9 AstraZeneca                               

                8.10 Aeriel BioPharma                   

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environmentGlobal Medical Aesthetics Devices Market, Medical Aesthetics Devices Market research report, Medical Aesthetics Devices industry analysis
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Migraine Drug Market, By Region, From 2020 to 2025 (USD Billion)
  2. Global Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  3. Global Preventive Market, By Region, From 2020 to 2025 (USD Billion)
  4. Global abortive Market, By Region, From 2020 to 2025 (USD Billion)
  5. Global Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  6. Global Triptents Market, By Region, From 2020 to 2025 (USD Billion)
  7. Global Ergots Market, By Region, From 2020 to 2025 (USD Billion)
  8. Global Others Market, By Region, From 2020 to 2025 (USD Billion)
  9. North America Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  10. North America Preventive Market, By Region, From 2020 to 2025 (USD Billion)
  11. North America abortive Market, By Region, From 2020 to 2025 (USD Billion)
  12. North America Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  13. North America Triptents Market, By Region, From 2020 to 2025 (USD Billion)
  14. North America Ergots Market, By Region, From 2020 to 2025 (USD Billion)
  15. North America Others Market, By Region, From 2020 to 2025 (USD Billion)
  16. United States Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  17. United States Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  18. Canada Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  19. Canada Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  20. Europe Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  21. Europe Preventive Market, By Region, From 2020 to 2025 (USD Billion)
  22. Europe abortive Market, By Region, From 2020 to 2025 (USD Billion)
  23. Europe Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  24. Europe Triptents Market, By Region, From 2020 to 2025 (USD Billion)
  25. Europe Ergots Market, By Region, From 2020 to 2025 (USD Billion)
  26. Europe Others Market, By Region, From 2020 to 2025 (USD Billion)
  27. U.K. Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  28. U.K. Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  29. Germany Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  30. Germany Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  31. France Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  32. France Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  33. Italy Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  34. Italy Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  35. Spain Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  36. Spain Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  37. Asia-Pacific Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  38. Asia-Pacific Preventive Market, By Region, From 2020 to 2025 (USD Billion)
  39. Asia-Pacific abortive Market, By Region, From 2020 to 2025 (USD Billion)
  40. Asia-Pacific Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  41. Asia-Pacific Triptents Market, By Region, From 2020 to 2025 (USD Billion)
  42. Asia-Pacific Ergots Market, By Region, From 2020 to 2025 (USD Billion)
  43. Asia-Pacific Others Market, By Region, From 2020 to 2025 (USD Billion)
  44. Japan Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  45. Japan Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  46. China Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  47. China Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  48. India Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  49. India Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  50. Australia Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  51. Australia Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  52. South Korea Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  53. South Korea Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  54. Latin America Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  55. Latin America Preventive Market, By Region, From 2020 to 2025 (USD Billion)
  56. Latin America abortive Market, By Region, From 2020 to 2025 (USD Billion)
  57. Latin America Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  58. Latin America Triptents Market, By Region, From 2020 to 2025 (USD Billion)
  59. Latin America Ergots Market, By Region, From 2020 to 2025 (USD Billion)
  60. Latin America Others Market, By Region, From 2020 to 2025 (USD Billion)
  61. Brazil Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  62. Brazil Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  63. Argentina Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  64. Argentina Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  65. Mexico Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  66. Mexico Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  67. Rest of Latin America Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  68. Rest of Latin America Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  69. Middle East & Africa Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  70. Middle East & Africa Preventive Market, By Region, From 2020 to 2025 (USD Billion)
  71. Middle East & Africa abortive Market, By Region, From 2020 to 2025 (USD Billion)
  72. Middle East & Africa Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  73. Middle East & Africa Triptents Market, By Region, From 2020 to 2025 (USD Billion)
  74. Middle East & Africa Ergots Market, By Region, From 2020 to 2025 (USD Billion)
  75. Middle East & Africa Others Market, By Region, From 2020 to 2025 (USD Billion)
  76. Middle East Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  77. Middle East Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)
  78. Africa Migraine Drug Market, By Treatment, From 2020 to 2025 (USD Billion)
  79. Africa Migraine Drug Market, By Therapeutic, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample